0.08
+0.0117(+16.18%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.07 |
| Day High | 0.1 |
| Day Low | 0.07 |
| 52-Week High | 2.9 |
| 52-Week Low | 0.07 |
| Volume | 63.2M |
| Average Volume | 23.09M |
| Market Cap | 892,046 |
| PE | -0.02 |
| EPS | -4.4 |
| Moving Average 50 Days | 0.27 |
| Moving Average 200 Days | 0.66 |
| Change | 0.01 |
If you invested $1000 in Hepion Pharmaceuticals, Inc. (HEPA) 10 years ago, it would be worth $0 as of March 12, 2025 at a share price of $0.084. Whereas If you bought $1000 worth of Hepion Pharmaceuticals, Inc. (HEPA) shares 5 years ago, it would be worth $2.66 as of March 12, 2025 at a share price of $0.084.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
GlobeNewswire Inc.
Jan 22, 2025 1:00 PM GMT
EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”)
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
GlobeNewswire Inc.
Dec 11, 2024 1:00 PM GMT
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hep
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
GlobeNewswire Inc.
Dec 02, 2024 1:00 PM GMT
Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B’s Late-Clinical Stage Candidate to Treat Parkinson’s Disease Hepion’s Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives